Bayer Plans $2.2 Billion Pharmaceutical Manufacturing Investment in Ohio
Bayer has announced plans to invest approximately $2.2 billion in a new pharmaceutical manufacturing site in New Albany, Ohio, marking one of the company’s major investments in its U.S. Pharmaceuticals business and reinforcing the country’s role in its global manufacturing and innovation strategy.
The planned facility will be developed at the New Albany International Business Park and is expected to expand Bayer’s pharmaceutical production capabilities while supporting the company’s growing portfolio of medicines. The investment builds on more than $7 billion that Bayer has spent on pharmaceutical research and development and manufacturing in the United States over the past five years.
According to Bayer, the Ohio project is intended to strengthen the company’s long-term ability to manufacture innovative medicines, respond to increasing demand and support patient access in the United States and international markets.
Bayer said the new site will incorporate a flexible, modular design that can accommodate both drug substance and drug product manufacturing. The campus is also expected to use advanced digital technologies and automation to create a modern production environment capable of supporting the company’s evolving pharmaceutical pipeline.
The initial manufacturing focus is expected to include medicines in oncology, cardiovascular disease and renal care, areas that represent important components of Bayer’s pharmaceutical portfolio.
“This landmark investment underscores our commitment,” said Bill Anderson, CEO of Bayer. “The new site will be home to manufacturing expertise and a skilled workforce that will strengthen our ability to deliver innovative, high-quality medicines to patients both in the United States and abroad.”
Ohio Site to Expand Bayer’s U.S. Manufacturing Footprint
The planned New Albany facility represents a significant expansion of Bayer’s pharmaceutical manufacturing footprint in the United States. The company already operates major pharmaceutical research, development, commercial and manufacturing activities across several U.S. locations.
Bayer’s U.S. Pharmaceuticals headquarters is located in Whippany, New Jersey, while the company also maintains sites in Pittsburgh, Pennsylvania; Berkeley, California; Cambridge, Massachusetts; Research Triangle Park, North Carolina; and San Diego, California.
The Ohio campus will complement these existing operations by adding new manufacturing capacity and capabilities to Bayer’s broader U.S. network.
Sebastian Guth, Global Chief Operating Officer of Bayer Pharmaceuticals and President of Bayer U.S., said the United States remains an important market for the company’s Pharmaceuticals division.
“The United States is a key market for Bayer’s Pharmaceuticals division. This expansion is another important step to grow our pharmaceuticals business and to meet the demand of our customers and patients in the U.S., our fastest-growing pharmaceuticals market, and beyond,” Guth said.
The investment comes as pharmaceutical companies continue to focus on manufacturing capacity, supply-chain resilience and the ability to respond to demand for medicines across major markets. For Bayer, the Ohio project is positioned as part of a broader effort to strengthen the company’s global Product Supply network while maintaining manufacturing capabilities in established locations around the world.
Modular Manufacturing Campus Planned
Bayer plans to develop the Ohio facility as a flexible and modular campus, allowing manufacturing capacity to be added in stages.
The first module is planned to focus on drug substance manufacturing, with operations expected to begin in 2031. A second module focused on drug product manufacturing is planned to follow in 2034.
The phased approach is intended to provide Bayer with flexibility as its pharmaceutical portfolio develops and manufacturing requirements evolve.
Drug substance manufacturing generally involves the production of the active pharmaceutical ingredient or other key medicinal substance that provides a drug with its therapeutic effect. Drug product manufacturing involves converting the active substance into the finished dosage form that can ultimately be supplied to patients.
By incorporating both capabilities within the planned campus, Bayer expects the Ohio site to become an important component of its pharmaceutical production infrastructure.
The company also intends to integrate digital and automation technologies into the facility. These technologies are expected to support modern manufacturing processes, operational efficiency and production consistency.
Rather than creating a conventional manufacturing site focused on a single production line, Bayer described the project as a flexible campus designed to support its expanding portfolio.
Focus on Oncology, Cardiovascular and Renal Medicines
The new Ohio manufacturing campus is initially expected to support Bayer’s growing portfolio in oncology, cardiovascular and renal care.
These therapeutic areas represent strategically important segments for the company and include medicines addressing diseases that affect large patient populations.
Bayer has developed and commercialized pharmaceutical products across multiple therapeutic areas, with cardiovascular and renal diseases representing established areas of activity and oncology becoming an increasingly important component of its pharmaceutical pipeline.
The company’s planned manufacturing investment could therefore provide additional infrastructure to support medicines as they progress through development, regulatory approval and commercialization.
The ability to establish manufacturing capacity alongside portfolio growth can also help pharmaceutical companies prepare for future product demand. Bayer’s modular approach is intended to provide room for the site to evolve as the company’s needs change.
Investment Expected to Create Hundreds of Jobs
Beyond pharmaceutical manufacturing, Bayer expects the project to contribute to employment and economic activity in Ohio.
The company anticipates creating approximately 600 high-value jobs at the completed site. These positions are expected to include roles requiring specialized expertise in pharmaceutical manufacturing, engineering, technology, quality, operations and related disciplines.
The construction phase is expected to generate approximately 1,500 construction jobs.
The development is therefore expected to have an economic impact extending beyond Bayer’s own workforce. Construction activity associated with the new campus is expected to involve workers and suppliers, while the completed facility will require a highly skilled workforce to operate its manufacturing and technology systems.
The planned presence at the New Albany International Business Park also positions Bayer within a broader business and innovation environment in Ohio.
The company said the site is expected to contribute to the state’s economic development while helping establish additional pharmaceutical manufacturing capabilities in the region.
Strengthening Supply Chain Resilience
Bayer views the planned Ohio facility as an important addition to its global Product Supply network.
Holger Weintritt, Head of Product Supply at Bayer’s Pharmaceuticals division, said the facility would strengthen the company’s ability to serve markets reliably.
“The facility will be a strong strategic addition to our global Product Supply network,” Weintritt said. “As we continue to invest in our existing manufacturing sites around the globe, our planned presence in Ohio will further enhance our ability to serve our markets with greater resilience and reliability.”
Supply-chain resilience has become an increasingly important consideration for pharmaceutical manufacturers. Production of medicines often depends on complex networks involving raw materials, active pharmaceutical ingredients, manufacturing facilities, packaging operations and distribution infrastructure.
A geographically diversified manufacturing network can provide companies with additional capacity and operational flexibility. Bayer’s planned Ohio investment is intended to complement its existing global network rather than replace its current manufacturing operations.
The company said it will continue investing in existing manufacturing locations around the world while establishing the new U.S. site.
Connecting Academic Innovation With Manufacturing
Bayer also plans to use the Ohio site as part of a broader U.S.-based collaboration ecosystem.
The company’s ambition is to connect academic innovation with advanced pharmaceutical manufacturing expertise. Such an ecosystem could provide opportunities for collaboration among pharmaceutical researchers, manufacturing specialists, technology developers and academic institutions.
The objective is to support the development of future-ready pharmaceutical production capabilities while creating stronger links between scientific innovation and industrial manufacturing.
Advanced manufacturing increasingly depends on technologies such as automation, digital production systems, data analytics and other tools designed to improve how pharmaceutical products are developed and produced. Bayer’s planned campus is expected to incorporate these capabilities as part of its manufacturing infrastructure.
The company said the collaboration ecosystem will help support future pharmaceutical production and contribute to the development of advanced manufacturing expertise in the United States.
Long-Term U.S. Commitment
Bayer’s $2.2 billion Ohio investment follows more than $7 billion in U.S. pharmaceutical research and development and manufacturing spending over the past five years.
The company characterized the latest project as part of its long-term growth strategy and its commitment to innovation and patient access.
The investment also reflects the importance of the United States to Bayer’s Pharmaceuticals business. With the U.S. described by Bayer as its fastest-growing pharmaceuticals market, the company expects demand from American patients and customers to remain an important driver of its operations.
At the same time, the planned facility is designed to serve markets beyond the United States, giving Bayer additional manufacturing capacity that can contribute to its international supply network.
For Bayer, establishing a major new manufacturing campus in Ohio therefore combines several objectives: expanding production capacity, strengthening supply-chain resilience, incorporating advanced technologies, creating highly skilled employment opportunities and establishing connections with the U.S. innovation ecosystem.
Facility Timeline and Future Role
Construction and development of the new campus will proceed in stages. The first manufacturing module, focused on drug substance production, is expected to become operational in 2031. Bayer plans to add the second module for drug product manufacturing in 2034.
The phased timeline gives the company several years to develop the infrastructure, workforce and manufacturing systems required for the site.
Once operational, the Ohio campus is expected to become an important addition to Bayer’s U.S. pharmaceutical network. Its combination of drug substance and drug product capabilities could allow the company to support multiple stages of pharmaceutical manufacturing while providing flexibility for future production needs.
The project also demonstrates Bayer’s continued investment in U.S. manufacturing alongside its research and development activities. By linking manufacturing with advanced technology and academic collaboration, the company aims to create a production environment capable of supporting its pharmaceutical portfolio over the longer term.
With approximately $2.2 billion committed to the project, hundreds of anticipated permanent positions and thousands of construction jobs, the New Albany development represents a substantial expansion of Bayer’s presence in Ohio.
As Bayer continues to develop medicines across oncology, cardiovascular disease and renal care, the company expects the new facility to play a role in meeting future production requirements and strengthening the reliability of its pharmaceutical supply network.
The planned investment ultimately positions the New Albany campus as a future manufacturing hub within Bayer’s broader U.S. and global Pharmaceuticals operations, combining advanced production capabilities, digital technologies, skilled employment and phased expansion to support the company’s long-term pharmaceutical strategy.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros.